Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01770158 |
|
Recruitment Status :
Terminated
(Recruitment goal cannot be achieved any more as only 8 patients have been recruited since start of the study in 2012.)
First Posted : January 17, 2013
Last Update Posted : April 9, 2018
|
Sponsor:
University of Ulm
Information provided by (Responsible Party):
Jochen Greiner, University of Ulm
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a non-interventional multi-center study (NIS) in adult patients with AML in first complete remission with measurable minimal residual disease (MRD). Patients are eligible when gene status was already determined for previous induction and consolidation therapy of AML and showed carrier of NPM1, CBFβ-MYH11, or MLL-AF9 mutation. The study objective is to observe the impact of pre-emptive therapy with histamine dihydrochloride (HDC) and interleukin-2 (IL-2) with regard to assess leukemia-free survival/time to relapse and to monitor MRD level trend over time. HDC and IL-2 are approved drugs for AML patients in first complete remission. Therapy is administered for 10 treatment cycles as outlined in the Summary of Product Characteristics.
| Condition or disease |
|---|
| Acute Myeloid Leukemia |
| Study Type : | Observational |
| Actual Enrollment : | 8 participants |
| Observational Model: | Other |
| Time Perspective: | Prospective |
| Official Title: | Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS) |
| Study Start Date : | October 2012 |
| Actual Primary Completion Date : | March 27, 2018 |
| Actual Study Completion Date : | March 27, 2018 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Core binding factor acute myeloid leukemia
Cytogenetically normal acute myeloid leukemia
Familial acute myeloid leukemia with mutated CEBPA
Primary Outcome Measures :
- leukemia-free survival / cumulative incidence of relapse [ Time Frame: two years ]
Secondary Outcome Measures :
- Toxicity induced by the preemptive treatment with Ceplene and IL-2 [ Time Frame: 18 months ]Duration of neutropenia and leukopenia after each treatment cycle, incidence of infections, duration of hospitalization
- Overall survival [ Time Frame: two years ]
Other Outcome Measures:
- Assessment of quality of life [ Time Frame: two years ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Adult patients with acute myeloid leukaemia (AML) in first remission following completion of consolidation therapy and concomitantly treated with interleukin-2 (IL-2) which will receive treatment with CEPLENE® for the first time. Patients are eligible when gene status was already determined for previous induction and consolidation therapy of AML and showed carrier of NPM1, CBFβ-MYH11, or MLL-AF9 mutation.
Criteria
Patient eligibility criteria in accordance to the summary of Product Characteristics:
- Patients with confirmed diagnosis of acute myeloid leukemia according to the World Health Organization (WHO) classification (including de novo AML, t-AML and s-AML) in first complete remission (defined as less than 5% blasts in a normocellular bone marrow assessed prior to the treatment start)
- AMLSG BiO participation incl. favourable opinion
- Presence of NPM1 mutation, CBFB-MYH11 or MLL-AF9 fusion genes as assessed in one of the central AMLSG reference laboratories.
- Measurable MRD values (non-negative values after consolidation therapy or increase in values over the threshold during follow-up in complete remission)
- The patient must be informed of the observation and written informed consent regarding data privacy obtained.
- Consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician and all other treating physicians about observation participation
- No continuing systemic treatment with clonidine, steroids, and/or H2 receptor blocking agents.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01770158
Locations
| Germany | |
| Vivantes Hospital Neukölln | |
| Berlin, Germany, 12351 | |
| Charite, University Medical School of Berlin | |
| Berlin, Germany, 13353 | |
| Darmstadt Clinic | |
| Darmstadt, Germany, 64283 | |
| University Hospital of Düsseldorf | |
| Düsseldorf, Germany, 40225 | |
| Malteser Krankenhaus St. Franziskus Hospital | |
| Flensburg, Germany, 24939 | |
| University of Freiburg | |
| Freiburg, Germany, 79106 | |
| Wilhelm-Anton-Hospital gGmbH Goch | |
| Goch, Germany, 47674 | |
| Klinikum Region Hannover GmbH, Krankenhaus Siloah | |
| Hannover, Germany, 30449 | |
| Hannover Medical School | |
| Hannover, Germany, 30625 | |
| Saarland University Medical Center | |
| Homburg/Saar, Germany, 66421 | |
| Städtisches Klinikum Karlsruhe gGmbH | |
| Karlsruhe, Germany, 76133 | |
| University Medical Center Schleswig Holstein | |
| Kiel, Germany, 24116 | |
| Caritas-Krankenhaus Lebach | |
| Lebach, Germany, 66822 | |
| Hospital of Lüdenscheid | |
| Lüdenscheid, Germany, 58515 | |
| University Clinic Magdeburg | |
| Magdeburg, Germany, 39120 | |
| Hospital of Schwäbisch Gmünd | |
| Mutlangen, Germany, 73557 | |
| University Hospital rechts der Isar | |
| München, Germany, 81675 | |
| Hospital of Passau | |
| Passau, Germany, 94032 | |
| Hospital of Traunstein | |
| Traunstein, Germany, 83278 | |
| Klinikum Mutterhaus der Borromäerinnen | |
| Trier, Germany, 54290 | |
| University Hospital of Ulm | |
| Ulm, Germany, 89520 | |
| Helios Klinikum Wuppertal | |
| Wuppertal, Germany, 42283 | |
Sponsors and Collaborators
University of Ulm
Investigators
| Principal Investigator: | Jochen Greiner, MD | University Hospital of Ulm |
| Responsible Party: | Jochen Greiner, Prof. Dr. Jochen Greiner, University of Ulm |
| ClinicalTrials.gov Identifier: | NCT01770158 History of Changes |
| Other Study ID Numbers: |
AMLSG18-12 |
| First Posted: | January 17, 2013 Key Record Dates |
| Last Update Posted: | April 9, 2018 |
| Last Verified: | April 2018 |
Keywords provided by Jochen Greiner, University of Ulm:
|
Acute myeloid leukemia (AML) Histamine Dihydrochloride Interleukin-2 |
Additional relevant MeSH terms:
|
Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasm, Residual Neoplasms by Histologic Type Neoplasms Neoplastic Processes Pathologic Processes Interleukin-2 Histamine Histamine phosphate |
Antineoplastic Agents Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Histamine Agonists Histamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |